Pass-Through to Shareholders in the New Jersey Research and Development (R&D) tax credit context refers to the mechanism of transferring corporate-level tax credits to the individual tax returns of business owners. Under current New Jersey statutes, this mechanism is strictly prohibited, as the credit is legally confined to the Corporation Business Tax (CBT) and cannot be utilized to offset individual Gross Income Tax (GIT) liabilities.

The exclusion of individual shareholders from the direct benefit of the New Jersey R&D tax credit represents a significant departure from federal tax treatment under Internal Revenue Code (IRC) Section 41, where credits earned by pass-through entities such as S-corporations and partnerships flow seamlessly to the owners’ personal tax returns. In New Jersey, the credit—governed by N.J.S.A. 54:10A-5.24—is designed exclusively as a corporate incentive. This structural limitation creates a unique fiscal environment for the state’s burgeoning technology and life sciences sectors, particularly for small to mid-sized firms organized as S-corporations or partnerships. While these entities may generate substantial credits through qualified research conducted within the state, the lack of a pass-through mechanism often leaves these credits stranded at the entity level, where tax liabilities are frequently minimal. To mitigate this, the state has developed sophisticated alternative monetization pathways, most notably through the New Jersey Economic Development Authority (NJEDA), allowing unprofitable firms to sell their credits to profitable corporations. Understanding this landscape requires a deep dive into the statutory framework, the specific administrative guidance provided by the New Jersey Division of Taxation in Technical Bulletin TB-114, and the complex interplay between the Corporation Business Tax Act and the Gross Income Tax Act.

The Legislative Foundation of the New Jersey R&D Tax Credit

The New Jersey Research and Development Tax Credit was established to incentivize businesses to perform high-tech research and development activities within the state. The primary statutory authority for the credit is found in N.J.S.A. 54:10A-5.24, which allows a taxpayer a credit against the tax imposed by the Corporation Business Tax Act.

Statutory Authority and the 2018 Recoupling

The history of the New Jersey R&D credit is marked by a major transition that occurred in 2018. Prior to this period, the state credit was based on the federal IRC Section 41 as it existed on June 30, 1992. This "frozen" conformity created significant administrative challenges for taxpayers, who were forced to maintain separate records for federal and state purposes to account for over two decades of federal legislative changes that New Jersey had not adopted.

With the passage of P.L. 2018, c. 48, New Jersey "recoupled" its R&D credit with the modern version of the federal IRC. This legislative shift significantly simplified the calculation process by mandating that taxpayers use the same methods—either the Regular Credit method or the Alternative Simplified Credit (ASC) method—for both federal and state filings. However, even with this recoupling, the state maintained its rigid stance on the non-pass-through nature of the credit.

Defining the Taxpayer and the Tax Base

Under N.J.S.A. 54:10A-5.24, the credit is explicitly granted against the tax imposed pursuant to Section 5 of P.L. 1945, c. 162, which is the Corporation Business Tax. The law defines "qualified research expenses" and "basic research payments" in accordance with federal standards but adds a crucial geographic restriction: the expenditures must be for research conducted in this State.

This definition of the "taxpayer" as a corporation subject to the CBT is the root of the pass-through limitation. Because individual shareholders and partners pay tax under the New Jersey Gross Income Tax Act (Title 54A), and because the R&D credit is not a credit provided for in Title 54A, there is no legal basis for an individual to claim the credit on their personal return.

The Meaning and Implications of Pass-Through Restrictions

In the broader tax world, "pass-through" refers to the treatment of entities like S-corporations, partnerships, and Limited Liability Companies (LLCs) where the entity itself does not pay income tax. Instead, the income, losses, and tax credits "pass through" to the owners based on their percentage of ownership.

Federal vs. New Jersey Pass-Through Comparison

The disparity between federal and New Jersey treatment of the R&D credit is stark, as illustrated in the following table:

Feature	Federal R&D Credit (IRC § 41)	New Jersey R&D Credit (NJSA 54:10A-5.24)
Applicable Tax	Federal Income Tax	New Jersey Corporation Business Tax (CBT)
S-Corporation Treatment	Passes through to shareholders via Schedule K-1	Restricted to entity-level CBT liability
Partnership Treatment	Passes through to partners via Schedule K-1	Only available to corporate partners for their CBT
Refundability	Generally non-refundable (payroll offset for startups)	Non-refundable (but transferable via NJEDA)
Geographic Scope	Anywhere in the United States	Conducted within New Jersey borders only

The "Stranded Credit" Problem for S-Corporations

For a New Jersey S-corporation, the inability to pass through the R&D credit often leads to "stranded" credits. Most S-corporations in New Jersey pay only the statutory minimum tax, which ranges from $500 to $2,000 based on their gross receipts. Because the R&D credit can only offset the CBT liability and cannot reduce the tax below the statutory minimum, an S-corporation that earns a $50,000 R&D credit but only has a $2,600 CBT liability (where $2,000 is the minimum) can only utilize $600 of the credit in the current year. The remaining $49,400 must be carried forward to future years, providing no immediate benefit to the shareholders who may be paying tens of thousands in Gross Income Tax on the same income.

Administrative Guidance: Analysis of Technical Bulletin TB-114

The New Jersey Division of Taxation provides the most detailed interpretative guidance on the R&D credit through Technical Bulletin TB-114. This document serves as the regulatory "playbook" for corporations, tax professionals, and auditors.

Entity-Specific Rules in TB-114

TB-114 addresses the nuances of how different business structures interact with the R&D credit. The Division's position is clear: the R&D credit is for all Corporation Business Tax taxpayers, but the application of the credit depends on the entity's classification.

S-Corporations and QSSSs

For S-corporations and Qualified Subchapter S Subsidiaries (QSSS), the credit is confined to the entity level. TB-114 specifies that these entities claim the credit on their own CBT return (Form CBT-100S). If the S-corporation has income that is taxed for federal purposes (such as built-in gains), the R&D credit can offset the New Jersey tax on that income, but it cannot flow through to the shareholders’ Form NJ-1040.

Partnerships and Corporate Partners

A partnership conducting research in New Jersey does not claim the R&D credit itself. Instead, it calculates the qualified research expenditures and allocates them to its partners. TB-114 explains that only those partners that are themselves corporations subject to the CBT can take their share of these expenditures and use them to calculate an R&D credit on their own corporate returns. Individual partners (natural persons) receive no benefit from these R&D expenses for New Jersey tax purposes.

Disregarded Entities

In the case of disregarded entities (such as a single-member LLC owned by a corporation), the activities of the entity are treated as if they were performed directly by the corporate owner. Thus, if the single-member LLC performs R&D in New Jersey, the corporate parent includes those expenses in its own R&D credit calculation on its CBT-100 return.

Interaction with the BAIT (Pass-Through Business Alternative Income Tax)

In 2020, New Jersey enacted the BAIT to allow pass-through entities to pay an entity-level tax to help their members avoid the federal SALT deduction cap. There has been persistent hope among taxpayers that the R&D credit could be used against the BAIT. However, TB-114 and related BAIT guidance clarify that there is no R&D credit for the purposes of the BAIT.

While an S-corporation can use the R&D credit to reduce its CBT liability, which may indirectly affect its overall tax posture, the R&D credit cannot be used as a dollar-for-dollar offset against the BAIT liability itself. This reinforces the state's policy of keeping the R&D credit strictly within the CBT silo.

Calculation Methodologies and Compliance

The calculation of the New Jersey R&D credit is a multi-step process that requires careful adherence to both federal definitions and state-specific limitations.

Qualified Research Expenses (QREs)

To qualify for the credit, expenditures must meet the federal "Four-Part Test" under IRC Section 41(d) and must be incurred for research conducted in New Jersey. The components of QREs include:

• Wages: Salaries for employees directly performing, supervising, or supporting the research in New Jersey.
• Supplies: Tangible property (excluding land and depreciable property) used in the research process within New Jersey.
• Contract Research: 65% of the amounts paid to third parties for research conducted on the taxpayer's behalf in New Jersey.
• Basic Research Payments: Payments to qualified organizations (like universities) for original investigation to advance scientific knowledge.

The Four-Part Test in a New Jersey Context

The Division of Taxation follows federal case law and IRS regulations to determine if an activity qualifies as "qualified research".

• Permitted Purpose: The activity must relate to a new or improved function, performance, reliability, or quality of a business component.
• Elimination of Uncertainty: The taxpayer must have intended to discover information to eliminate uncertainty regarding the capability, method, or design of the business component.
• Process of Experimentation: Substantially all of the activities must constitute a process of experimentation, involving the evaluation of alternatives through modeling, simulation, or trial and error.
• Technological in Nature: The research must fundamentally rely on the principles of physical or biological sciences, engineering, or computer science.

Regular Credit vs. Alternative Simplified Credit (ASC)

New Jersey requires taxpayers to use the same method for state purposes as they used for their federal R&D credit.

The Regular Method

The Regular Method is incremental and depends on a "base amount" determined by the taxpayer's historical R&D intensity.

• Formula: 10% of (Current Year NJ QREs - NJ Base Amount) + 10% of NJ Basic Research Payments.
• Base Amount: Calculated using a fixed-base percentage (ratio of R&D to gross receipts from a historical period) multiplied by the average gross receipts for the prior four years.

The ASC Method

The ASC method is generally preferred by companies that do not have the historical data required for the regular method or whose R&D spending has been volatile.

• Formula: 10% of (Current Year NJ QREs - 50% of the average NJ QREs for the prior 3 years).
• Startup Rule: If the taxpayer has no QREs in any of the three preceding years, the credit is 6% of the current year's QREs.

Statutory Minimum Tax and Credit Caps

New Jersey law imposes several limitations on the actual use of the credit. First, the credit cannot reduce the tax liability below the statutory minimum CBT. The minimum tax is based on New Jersey gross receipts:

New Jersey Gross Receipts	Minimum Tax
Less than $100,000	$500
$100,000 to $249,999	$750
$250,000 to $499,999	$1,000
$500,000 to $999,999	$1,500
$1,000,000 or more	$2,000

For members of an affiliated or controlled group with a total payroll of $5,000,000 or more, the minimum tax is fixed at $2,000. Additionally, for privilege periods beginning before January 1, 2012, the credit was limited to 50% of the tax liability; however, for periods beginning on or after that date, the 50% cap was removed, though the minimum tax floor remains.

Alternative Monetization: The NJEDA NOL Program

Because many innovative startups are pre-revenue or unprofitable, and because their R&D credits cannot pass through to shareholders, New Jersey offers a unique "safety valve" through the New Jersey Economic Development Authority (NJEDA).

The Technology Business Tax Certificate Transfer Program

This program allows eligible, unprofitable technology and biotechnology companies to sell their unused New Jersey net operating losses (NOLs) and R&D tax credits for cash. This provides an immediate "financial lifeline" that can be used for growth, operations, and further R&D.

Eligibility Criteria for Selling Credits

To participate in the program, a business must meet several strict requirements:

• Industry Focus: Must be a technology or biotechnology company providing a scientific process, product, or service.
• Size Limitation: Fewer than 225 U.S. employees.
• Intellectual Property: Must own, have filed for, or have a license to use protected, proprietary intellectual property (patent or registered copyright).
• Profitability: Must have a net loss or no tax liability.
• Employee Count: Minimum New Jersey employee requirements apply based on the age of the company (e.g., at least 1 full-time employee if formed less than 3 years; 10 if more than 5 years).

Program Statistics and Impact

The NJEDA’s transfer program is widely regarded as one of the most successful state-level innovation incentives in the country.

Metric	Achievement
Total Economic Impact	$28.1 Billion since 1999
Companies Supported	Nearly 600
Jobs Created/Maintained	31,200 estimated
Survival Rate	72% (vs. 36% industry benchmark)
Annual Funding Pool	$75 Million
Typical Purchase Price	At least 80% of face value

In 2024, the program disbursed $30 million in credits to startups. This mechanism effectively creates a "market-based pass-through" where the value of the credit is realized as cash for the entity, rather than a tax reduction for the owners.

Combined Group Filing and Credit Sharing

With the enactment of mandatory combined reporting in 2019, the management of R&D credits became significantly more complex for corporate groups.

Unitary Business Principles

Groups of companies engaged in a "unitary business" under common ownership must file a single return (Form CBT-100U). Within this group, members are categorized as either "taxable members" (those with nexus in New Jersey) or "non-taxable members".

Sharing the R&D Credit

The rules for sharing R&D credits within a combined group are nuanced:

• Generation: Any member of the combined group (taxable or non-taxable) can contribute to the qualified research expenses of the group, provided the research is conducted in New Jersey.
• Utilization: Only taxable members of the group can utilize the credit to offset their share of the group’s CBT liability.
• Sharing: By default, credits earned by one taxable member can be shared with other taxable members of the same group to offset their liability. However, a member can elect not to share its credit by filling in the appropriate oval on Form 306.
• Minimum Tax Floor: Even when sharing credits, no member’s tax liability can be reduced below its individual statutory minimum assessment.

Recent Regulatory Changes and Federal Conformity

The landscape of the New Jersey R&D credit is constantly evolving due to shifts in federal law and state administrative policy.

Conformity with IRC Section 174

One of the most critical recent developments concerns federal changes to IRC Section 174, which now requires taxpayers to amortize research and experimental expenditures over five years rather than expensing them immediately.

New Jersey’s TB-114 addresses this by providing a pathway for taxpayers to "decouple" from this amortization requirement for CBT purposes. Under certain conditions, a business can deduct New Jersey qualified research expenditures in the same year they claim the R&D credit, effectively providing a double benefit (a deduction and a credit) that is no longer available at the federal level.

Cannabis and the R&D Credit

Following the legalization of recreational cannabis, New Jersey has taken steps to support the industry by decoupling from federal IRC Section 280E, which prohibits businesses involved in "trafficking" controlled substances from taking standard business deductions. Starting January 1, 2023, registered cannabis licensees in New Jersey can treat expenses that would otherwise be disallowed under 280E as qualified research expenses for the New Jersey R&D credit, provided they meet the four-part test.

The Federal Payroll Tax Credit Election

For federal purposes, certain small businesses can elect to use up to $250,000 (now increased under the Inflation Reduction Act) of their R&D credit to offset the employer portion of Social Security payroll taxes. New Jersey law (N.J.S.A. 54:10A-5.24(c)) clarifies that businesses making this federal election are still eligible to use those same expenditures to calculate the New Jersey R&D credit against their CBT liability.

Compliance, Documentation, and Audit Procedures

Because the R&D credit is a high-value incentive, it is a frequent target for audit by the New Jersey Division of Taxation.

The Statute of Limitations

Generally, a taxpayer has four years from the date of filing a return to claim or amend an R&D credit. If the IRS makes an adjustment to the federal R&D credit, the taxpayer is required to file an amended New Jersey return reflecting that adjustment if it pertains to New Jersey-based research.

Documentation Best Practices

To survive a state audit, companies must maintain "contemporaneous" documentation. This means records must be created at the time the research is performed, not reconstructed years later. Recommended documents include:

• Project Lists: A comprehensive list of all R&D projects with descriptions of the technological uncertainties involved.
• Time Tracking: Records showing the percentage of time each employee spent on qualified activities.
• Lab Notes and Prototypes: Physical or digital evidence of the "process of experimentation," such as testing results, failed prototypes, and alternative designs.
• General Ledger Detail: Invoices for supplies and payments to contractors clearly linked to specific research projects.

Comprehensive Case Study: BioGen NJ

To understand the practical application of the pass-through limitations and the strategic options available, consider the following example of a hypothetical New Jersey biotechnology firm.

Company Profile: BioGen NJ

• Location: New Brunswick, NJ (located in an Innovation Zone).
• Structure: S-Corporation owned by two PhD scientists.
• Operations: Developing a novel protein for cancer treatment.
• Financials (2024): $2,000,000 in QREs (wages for researchers); $500,000 in NJ gross receipts; $50,000 in net income.

Year 1: Credit Generation and Stranding

BioGen NJ calculates its R&D credit using the ASC method.

• Credit Calculation: $2,000,000 (Current QREs) - $500,000 (50% of 3-year average) = $1,500,000 excess.
• Credit Amount: $1,500,000 \times 10% = $150,000.
• CBT Liability: With $50,000 in income, the tax at S-corp rates is minimal, but they owe the $1,500 statutory minimum tax.
• Usage: The credit cannot reduce the tax below $1,500. Therefore, BioGen NJ uses $0$ of its $150,000 credit.
• Shareholder Impact: The two owners pay approximately $4,000 each in Gross Income Tax on their share of the company’s profit. They cannot use the $150,000 credit to offset this $8,000 total bill.

Year 2: Strategic Monetization

Recognizing the credit is stranded, the owners apply for the NJEDA NOL Program.

• Program Benefit: Because they are in an Innovation Zone, they are part of the $15 million set-aside pool.
• The Sale: They find a profitable New Jersey utility company that agrees to buy the $150,000 R&D credit for $90$ cents on the dollar.
• Net Result: BioGen NJ receives a cash payment of $135,000.
• Utilization: They use this cash to hire a third researcher and purchase high-end lab supplies, directly fueling their next phase of growth.

Year 3: Scaling and Combined Filing

BioGen NJ is acquired by a larger pharmaceutical group, "GlobalPharm," and becomes a taxable member of their New Jersey combined group.

• Credit Sharing: The $150,000 R&D credit generated by BioGen NJ (now a subsidiary) is now used to offset the multi-million dollar CBT liability of the entire GlobalPharm group in New Jersey.
• Value Realization: Through this corporate structure, the credit finally provides its full tax-offset value, demonstrating why the pass-through limitation favors larger corporate integrations over independent S-corps.

Comparative Analysis: New Jersey vs. Neighboring States

To understand why the pass-through limitation is such a point of contention, it is helpful to look at how neighboring states treat the credit.

Pennsylvania

Pennsylvania offers an R&D credit that is also generally non-refundable and limited to 10% of the incremental increase in expenses. However, Pennsylvania allows for a much more robust "secondary market" where businesses can sell credits to any other taxpayer. Crucially, Pennsylvania’s credit can be used to offset the Corporate Net Income Tax (CNIT), which has different pass-through rules than New Jersey’s CBT.

California

California is often cited as the gold standard for R&D incentives. While its credit is also non-refundable, it has a much more generous carry-forward period (indefinite) and higher credit percentages for certain types of research. California's treatment of S-corporations is more favorable, allowing a 1/3 portion of the credit to be used at the entity level and the remaining 2/3 to pass through to shareholders—a model that New Jersey reformers often point to as a potential solution.

Legislative Outlook: The Push for Reform

The current restriction on pass-through is not without its critics in the New Jersey Legislature.

Analysis of Bill A3403 and S2707

In recent sessions, multiple bills have been introduced to address the R&D credit’s limitations.

• Bill A3403: Specifically seeks to allow S-corporations to elect to transfer their CBT credits to their shareholders. The bill’s sponsors argue that the current system penalizes small businesses that choose the S-corp structure, effectively making the R&D credit a "C-corp only" benefit in practice.
• Bill S2707: Proposes to increase the R&D credit rate from 10% to 15% and, more importantly, to make the credit refundable for certain small businesses. Refundability would solve the pass-through problem by allowing the state to simply issue a check to the business for the value of the credit, which the business could then distribute to shareholders or reinvest.

Fiscal and Political Headwinds

The primary obstacle to these reforms is the "fiscal note"—the estimated cost to the state budget. Allowing credits to pass through to the Gross Income Tax would directly reduce revenues that are constitutionally dedicated to property tax relief. In a state with some of the highest property taxes in the nation, any policy that threatens that revenue stream faces significant political resistance.

Final Thoughts

The New Jersey Research and Development Tax Credit is a cornerstone of the state's economic identity, yet it remains one of the most structurally complex incentives for small businesses to navigate. The meaning of "pass-through to shareholders" in this context is essentially a story of a missing link: the legal barrier that prevents innovation-driven credits from reaching the personal tax returns of the entrepreneurs who lead these companies.

For the business owner, this means that the R&D credit must be managed not as a personal tax benefit, but as a strategic corporate asset. In the absence of a direct pass-through, the "lifeline" provided by the NJEDA’s transfer program remains the most viable path for pre-revenue and pre-profit firms to extract value from their intellectual investments. Meanwhile, established corporate groups continue to benefit from the sharing of credits within unitary returns, reinforcing the credit's role as a tool for corporate-scale development.

As the "innovation economy" continues to grow in hubs like Newark, Jersey City, and the Princeton corridor, the pressure to reform these pass-through limitations will likely continue. Until such legislative changes occur, a nuanced understanding of TB-114, the NJEDA’s eligibility rules, and the mechanics of the Corporation Business Tax remains essential for any professional seeking to maximize the return on New Jersey-based research and development. The credit stands as a testament to the state's commitment to high-tech growth, provided that growth occurs within the strictly defined boundaries of its corporate tax system.